CSIMarket Company Name, Ticker, Customers, else..
 
Neurosense Therapeutics Ltd  (NASDAQ: NRSN)
 
Price: $6.9500 $-0.45 -6.081%
Day's High: $7.179999828338623 Week Perf: 4.98 %
Day's Low: $ 6.73 30 Day Perf: 1599.27 %
Volume (M): 6,800 52 Wk High: $ 7.50
Volume (M$): $ 0 52 Wk Avg: $1.06
Open: $7.18 52 Wk Low: $0.25



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 1
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company develops and commercializes pharmaceutical product candidates, with its lead candidate named PrimeC. It faces risks such as the need for substantial additional financing, challenges in obtaining regulatory approval, limited clinical data, and market competition.


   Company Address: 11 HaMenofim Street Herzliya 4672562
   Company Phone Number: -9-7996183   Stock Exchange / Ticker: NASDAQ NRSN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stocks on the Move

Neurosense Therapeutics Ltds ALS Treatment Success Propels Hope for Patients and Investors

Published Wed, Jul 3 2024 11:46 AM UTC

Neurosense Therapeutics Ltd Trails Market Performance with ALS Treatment SuccessNeurosense Therapeutics Ltd (NASDAQ: NRSN) shares have been trailing the performance of the entire market in recent weeks. Despite this, the company has achieved significant success in its phase 2b trial for an amyotrophic lateral sclerosis (ALS) treatment called PrimeC, which has shown a 36% slo...
Stock Offering

NeuroSense Therapeutics Enters Securities Purchase Agreement, Impacting Shareholders

Published Wed, Apr 10 2024 11:16 PM UTC


NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has recently announced its entry into a securities purchase agreement, marking a significant development in the company s efforts to develop novel treatments for severe neurodegenerative diseases. This agreement will have a direct impact on shareholders, as they will play a crucial role in determining the success and growth of...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.16
Working Capital Ratio 0.63
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -8.8 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.17 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -695,313
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.